|
Aurisco Pharmaceutical Co., Ltd. (605116.SS) DCF -Bewertung
CN | Healthcare | Biotechnology | SHH
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Aurisco Pharmaceutical Co.,Ltd. (605116.SS) Bundle
Verbessern Sie Ihre Anlagestrategie mit der DCF -Taschenrechnerin von Aurisco Pharmaceutical Co., Ltd. (605116S)! Überprüfen Sie reale Finanzdaten, passen Sie Wachstumsprojektionen und -kosten an und beobachten Sie sofort, wie sich diese Modifikationen auf den inneren Wert von Aurisco auswirken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 581.6 | 721.4 | 803.4 | 1,008.1 | 1,262.5 | 1,534.3 | 1,864.7 | 2,266.1 | 2,754.0 | 3,346.9 |
| Revenue Growth, % | 0 | 24.04 | 11.36 | 25.48 | 25.24 | 21.53 | 21.53 | 21.53 | 21.53 | 21.53 |
| EBITDA | 234.8 | 223.9 | 247.4 | 313.2 | 414.4 | 509.7 | 619.4 | 752.7 | 914.8 | 1,111.8 |
| EBITDA, % | 40.36 | 31.04 | 30.8 | 31.07 | 32.82 | 33.22 | 33.22 | 33.22 | 33.22 | 33.22 |
| Depreciation | 27.9 | 32.0 | 54.8 | 70.8 | 81.6 | 90.7 | 110.2 | 133.9 | 162.7 | 197.8 |
| Depreciation, % | 4.8 | 4.44 | 6.82 | 7.02 | 6.47 | 5.91 | 5.91 | 5.91 | 5.91 | 5.91 |
| EBIT | 206.9 | 191.9 | 192.7 | 242.4 | 332.7 | 419.0 | 509.2 | 618.8 | 752.1 | 914.0 |
| EBIT, % | 35.57 | 26.6 | 23.98 | 24.05 | 26.35 | 27.31 | 27.31 | 27.31 | 27.31 | 27.31 |
| Total Cash | 265.1 | 564.1 | 444.6 | 391.7 | 545.8 | 801.5 | 974.1 | 1,183.8 | 1,438.7 | 1,748.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 135.1 | 142.8 | 140.7 | 222.1 | 290.8 | 324.1 | 393.9 | 478.7 | 581.7 | 707.0 |
| Account Receivables, % | 23.23 | 19.8 | 17.52 | 22.03 | 23.03 | 21.12 | 21.12 | 21.12 | 21.12 | 21.12 |
| Inventories | 240.2 | 237.8 | 326.8 | 444.9 | 509.8 | 612.1 | 743.8 | 904.0 | 1,098.6 | 1,335.1 |
| Inventories, % | 41.3 | 32.96 | 40.68 | 44.14 | 40.38 | 39.89 | 39.89 | 39.89 | 39.89 | 39.89 |
| Accounts Payable | 79.0 | 97.0 | 137.3 | 115.2 | 173.6 | 212.6 | 258.4 | 314.0 | 381.6 | 463.8 |
| Accounts Payable, % | 13.57 | 13.45 | 17.09 | 11.43 | 13.75 | 13.86 | 13.86 | 13.86 | 13.86 | 13.86 |
| Capital Expenditure | -72.5 | -158.8 | -250.6 | -216.2 | -305.5 | -341.6 | -415.1 | -504.5 | -613.1 | -745.1 |
| Capital Expenditure, % | -12.46 | -22.01 | -31.2 | -21.45 | -24.2 | -22.26 | -22.26 | -22.26 | -22.26 | -22.26 |
| Tax Rate, % | 12.05 | 12.05 | 12.05 | 12.05 | 12.05 | 12.05 | 12.05 | 12.05 | 12.05 | 12.05 |
| EBITAT | 186.6 | 162.4 | 169.3 | 212.4 | 292.6 | 367.3 | 446.4 | 542.5 | 659.3 | 801.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -154.3 | 48.4 | -73.2 | -154.6 | -6.3 | 19.8 | -14.3 | -17.4 | -21.2 | -25.7 |
| WACC, % | 5.29 | 5.29 | 5.29 | 5.29 | 5.29 | 5.29 | 5.29 | 5.29 | 5.29 | 5.29 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -46.1 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -27 | |||||||||
| Terminal Value | -2,067 | |||||||||
| Present Terminal Value | -1,597 | |||||||||
| Enterprise Value | -1,643 | |||||||||
| Net Debt | -429 | |||||||||
| Equity Value | -1,214 | |||||||||
| Diluted Shares Outstanding, MM | 408 | |||||||||
| Equity Value Per Share | -2.98 |
What You'll Receive
- Adjustable Forecast Parameters: Effortlessly modify key variables (growth %, profit margins, WACC) to explore various scenarios.
- Industry-Specific Data: Pre-loaded financial information for Aurisco Pharmaceutical Co., Ltd. (605116SS) to kickstart your analysis.
- Instant DCF Calculations: The model automatically computes Net Present Value (NPV) and intrinsic value for your convenience.
- Customizable and Professional Design: A sleek Excel template tailored to meet your valuation requirements.
- Designed for Analysts and Investors: Perfect for assessing forecasts, validating strategies, and enhancing efficiency.
Key Features of Aurisco Pharmaceutical Co., Ltd. (605116SS)
- Comprehensive Financial Data: Gain access to precise pre-loaded historical performances and future forecasts.
- Tailorable Forecast Assumptions: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: Utilize user-friendly charts and summaries to effectively visualize valuation insights.
- Designed for All Levels: An intuitive layout catering to investors, CFOs, and consultants alike.
How It Functions
- Download: Obtain the pre-configured Excel file containing Aurisco Pharmaceutical Co., Ltd.'s (605116SS) financial information.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Instantly: Watch as the intrinsic value and NPV calculations refresh in real-time.
- Explore Scenarios: Develop various projections and quickly assess different outcomes.
- Make Informed Decisions: Leverage the valuation results to inform your investment strategy.
Why Choose This Calculator for Aurisco Pharmaceutical Co., Ltd. (605116SS)?
- Designed for Experts: A sophisticated tool utilized by analysts, financial officers, and industry consultants.
- Comprehensive Data: Aurisco's historical and forecasted financials are preloaded for enhanced precision.
- Flexibility in Scenarios: Effortlessly simulate various forecasts and assumptions.
- Clear and Precise Outputs: Automatically determines intrinsic value, NPV, and essential financial metrics.
- User-Friendly Experience: Step-by-step guidance makes the process seamless and straightforward.
Who Should Utilize Aurisco Pharmaceutical Co., Ltd. (605116SS) Products?
- Investors: Accurately assess the fair value of Aurisco Pharmaceutical Co., Ltd. (605116SS) prior to making investment choices.
- CFOs: Utilize a high-quality DCF model for financial reporting and comprehensive analysis.
- Consultants: Efficiently customize the template for client valuation reports.
- Entrepreneurs: Acquire insights into the financial modeling practices employed by leading pharmaceutical firms.
- Educators: Leverage it as an instructional resource to illustrate valuation techniques.
Contents of the Template
- Historical Data: Provides Aurisco Pharmaceutical's past financial performance and baseline forecasts.
- DCF and Levered DCF Models: Comprehensive templates designed to calculate the intrinsic value of Aurisco Pharmaceutical (605116SS).
- WACC Sheet: Pre-formulated calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Customize essential drivers such as growth rates, EBITDA percentages, and CAPEX assumptions.
- Quarterly and Annual Statements: A thorough analysis of Aurisco Pharmaceutical's financials.
- Interactive Dashboard: Dynamically visualize valuation outcomes and projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.